Cardiol Therapeutics Class Stock Book Value Per Share
| CRDL Stock | USD 1.45 0.03 2.03% |
Cardiol Therapeutics Class fundamentals help investors to digest information that contributes to Cardiol Therapeutics' financial success or failures. It also enables traders to predict the movement of Cardiol Stock. The fundamental analysis module provides a way to measure Cardiol Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cardiol Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.44 | 0.64 | |
| Tangible Book Value Per Share | 0.43 | 0.63 |
Cardiol | Book Value Per Share |
Cardiol Therapeutics Class Company Book Value Per Share Analysis
Cardiol Therapeutics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Cardiol Therapeutics Book Value Per Share | 0.43 X |
Most of Cardiol Therapeutics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cardiol Therapeutics Class is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cardiol Book Value Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Cardiol Therapeutics is extremely important. It helps to project a fair market value of Cardiol Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Cardiol Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cardiol Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cardiol Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Cardiol Book Value Per Share Historical Pattern
Today, most investors in Cardiol Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cardiol Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's book value per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cardiol Therapeutics book value per share as a starting point in their analysis.
Cardiol Therapeutics Book Value Per Share |
| Timeline |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
Cardiol Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, the book value per share of Cardiol Therapeutics Class is about 0.432 times. This is 125.41% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The book value per share for all United States stocks is 99.98% higher than that of the company.
Cardiol Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cardiol Therapeutics' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cardiol Therapeutics could also be used in its relative valuation, which is a method of valuing Cardiol Therapeutics by comparing valuation metrics of similar companies.Cardiol Therapeutics is currently under evaluation in book value per share category among its peers.
Cardiol Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cardiol Therapeutics from analyzing Cardiol Therapeutics' financial statements. These drivers represent accounts that assess Cardiol Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cardiol Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 118.3M | 83.0M | 100.7M | 43.1M | 49.6M | 93.1M | |
| Enterprise Value | 111.5M | 69.1M | 16.9M | (16.3M) | (18.7M) | (17.8M) |
Cardiol Fundamentals
| Return On Equity | -1.08 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 109.83 M | ||||
| Shares Outstanding | 81.6 M | ||||
| Shares Owned By Insiders | 3.91 % | ||||
| Shares Owned By Institutions | 9.50 % | ||||
| Number Of Shares Shorted | 893.32 K | ||||
| Price To Book | 15.80 X | ||||
| Price To Sales | 1,069 X | ||||
| Gross Profit | 78.76 K | ||||
| EBITDA | (29.59 M) | ||||
| Net Income | (28.13 K) | ||||
| Cash And Equivalents | 70.45 M | ||||
| Cash Per Share | 1.14 X | ||||
| Total Debt | 174.34 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 6.48 X | ||||
| Book Value Per Share | 0.43 X | ||||
| Cash Flow From Operations | (25.18 K) | ||||
| Short Ratio | 1.37 X | ||||
| Earnings Per Share | (0.39) X | ||||
| Target Price | 8.76 | ||||
| Beta | 0.7 | ||||
| Market Capitalization | 124.4 M | ||||
| Total Asset | 36.7 M | ||||
| Retained Earnings | (142.58 M) | ||||
| Working Capital | 51.63 M | ||||
| Net Asset | 36.7 M |
About Cardiol Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cardiol Therapeutics Class's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cardiol Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cardiol Therapeutics Class based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Cardiol Therapeutics Piotroski F Score and Cardiol Therapeutics Altman Z Score analysis. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.39) | Return On Assets (0.54) | Return On Equity (1.08) |
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.